Sona Nanotech To Host Investor Webinar To Discuss Clinical StudyOctober 17, 2025 4:04 PM EDT | Source: Sona Nanotech Inc.Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failin ...

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients ...

Core Viewpoint - Sona Nanotech Inc. has received approval to conduct a pilot clinical trial for its Targeted Hyperthermia Therapy (THT) aimed at treating late-stage melanoma patients, marking a significant step towards clinical application of its innovative cancer treatment technology [1][2]. Group 1: Clinical Trial Details - The pilot study will involve 30-40 patients and is contingent upon obtaining Investigational Testing Authorization from Health Canada [1][2]. - The anticipated start date for the pilot study is late 2025 or early 2026 [2]. Group 2: Company Background and Technology - Sona Nanotech is focused on developing Targeted Hyperthermia™, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, enhancing drug delivery and immune response [3]. - The therapy involves heating tumors to a range of 42-48°C using infrared light absorbed by gold nanorods, which are designed to be safe and effective [3]. - The company has developed proprietary methods for manufacturing gold nanoparticles that are free from cetyltrimethylammonium (CTAB), reducing toxicity risks associated with other technologies [4]. Group 3: Market Context - Melanoma cases in Canada have tripled over the past 30 years, with over 1,300 deaths annually, highlighting the urgent need for effective treatments [2].